Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia

Carolyn Owen; Sarah Eisinga; Versha Banerji; Nathalie Johnson; Alina S Gerrie; Andrew Aw; Christine Chen; Sue Robinson

doi:10.1016/j.leukres.2023.107372

Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia

Leuk Res. 2023 Oct:133:107372. doi: 10.1016/j.leukres.2023.107372. Epub 2023 Aug 19.

Authors

Carolyn Owen¹, Sarah Eisinga², Versha Banerji³, Nathalie Johnson⁴, Alina S Gerrie⁵, Andrew Aw⁶, Christine Chen⁷, Sue Robinson⁸

Affiliations

¹ Division of Hematology and Hematological Malignancies, Foothills Medical Centre, Calgary AB T2N 4N2, Canada. Electronic address: [email protected].
² Lymphoma Canada, Mississauga, ON, L5N 2W5, Canada.
³ Department of Hematology and Medical Oncology, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
⁴ Department of Medicine, Jewish General Hospital, Montreal QC H3T 1E2, Canada.
⁵ Division of Medical Oncology, Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC V5Z 4E6, Canada.
⁶ Division of Hematology, The Ottawa Hospital, Ottawa, Ontario K1Y 4E9, Canada.
⁷ Department of Medical Oncology, University of Toronto, and Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.
⁸ Division of Hematology, Dalhousie University, and GEII Health Sciences Centre, Halifax NS B3H 2Y9, Canada.

PMID: 37633157
DOI: 10.1016/j.leukres.2023.107372

Abstract

Following the recent publication of Canadian evidence-based guidelines for frontline treatment of chronic lymphocytic leukemia (CLL), the same group of clinicians developed guidelines for CLL in the relapsed/refractory (R/R) setting. The treatment of R/R CLL has changed significantly in the past few years, with many novel therapeutics available to hematologists across the country. These guidelines aim to standardize the management of CLL in the relapsed/refractory setting, using the best evidence currently available.

Keywords: CLL; Guidelines; Refractory; Relapse; SLL.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Canada
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Recurrence